Kainos Medicine Inc (284620) - Cash Flow Conversion Efficiency

Latest as of March 2025: -0.551x

Based on the latest financial reports, Kainos Medicine Inc (284620) has a cash flow conversion efficiency ratio of -0.551x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.97 Billion ≈ $-2.01 Million USD) by net assets (₩5.40 Billion ≈ $3.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Kainos Medicine Inc to measure how much of total assets are equity-financed.

Kainos Medicine Inc - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Kainos Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Kainos Medicine Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Kainos Medicine Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Kainos Medicine Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Bayu Buana Tbk JK:BAYU	-0.131x
Times Guaranty Limited NSE:TIMESGTY	-0.017x
Intchains Group Limited American Depositary Shares NASDAQ:ICG	-0.096x
West Coast Silver Ltd AU:WCE	-1.634x
Greggs PLC LSE:GRG	0.221x
Aurora Mobile Ltd NASDAQ:JG	0.048x
Yanaprima Hastapersada Tbk JK:YPAS	0.171x
Canfor Pulp Products Inc. TO:CFX	-0.064x

Annual Cash Flow Conversion Efficiency for Kainos Medicine Inc (2017–2024)

The table below shows the annual cash flow conversion efficiency of Kainos Medicine Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Kainos Medicine Inc (284620) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩1.79 Billion ≈ $1.21 Million	₩-9.71 Billion ≈ $-6.58 Million	-5.430x	-348.73%
2023-12-31	₩11.75 Billion ≈ $7.96 Million	₩-14.22 Billion ≈ $-9.64 Million	-1.210x	-179.71%
2022-12-31	₩26.11 Billion ≈ $17.69 Million	₩-11.30 Billion ≈ $-7.66 Million	-0.433x	+43.05%
2021-12-31	₩12.10 Billion ≈ $8.20 Million	₩-9.20 Billion ≈ $-6.23 Million	-0.760x	-23.35%
2020-12-31	₩12.35 Billion ≈ $8.37 Million	₩-7.61 Billion ≈ $-5.16 Million	-0.616x	-3385.22%
2019-12-31	₩9.91 Billion ≈ $6.71 Million	₩185.74 Million ≈ $125.88K	0.019x	+937.07%
2018-12-31	₩9.83 Billion ≈ $6.66 Million	₩-22.01 Million ≈ $-14.92K	-0.002x	+92.18%
2017-12-31	₩950.59 Million ≈ $644.20K	₩-27.23 Million ≈ $-18.45K	-0.029x	--

About Kainos Medicine Inc

KQ:284620 Korea Biotechnology

Market Cap

$24.10 Million

₩35.56 Billion KRW

Market Cap Rank

#24453 Global

#1722 in Korea

Share Price

₩1087.00

Change (1 day)

-8.81%

52-Week Range

₩977.00 - ₩1270.00

All Time High

₩28151.21